EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 7 Issue 2 2025

Assessing the Effectiveness of Seasonal Malaria Chemoprevention (SMC) in Reducing Severe Malaria Cases among Children

Kirenyo Nalubega F.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Seasonal Malaria Chemoprevention (SMC) is a targeted intervention aimed at reducing severe malaria cases among children in regions with seasonal malaria transmission. This review evaluated the effectiveness of SMC, its impact on reducing severe malaria cases, and its potential for broader integration within malaria control strategies. Using a narrative review methodology, the article synthesized evidence from existing studies to assess the efficacy, challenges, and future directions of SMC programs. SMC, involving monthly doses of sulfadoxine-pyrimethamine and amodiaquine during peak transmission seasons, has demonstrated remarkable success in lowering malaria incidence, hospitalizations, and mortality rates among children under five. The intervention also reduces the healthcare burden and mitigates long-term consequences such as cognitive impairment and stunting. However, challenges including drug resistance, logistical barriers, and community adherence limit its scalability and sustainability. To address these challenges, this review highlighted the need for novel drug regimens, integration with other malaria control measures, and the adoption of digital technologies for program optimization. Expanding the geographical scope of SMC and ensuring sustained investments are crucial for maximizing its impact. SMC remains a cornerstone in the fight against malaria, with the potential to significantly improve child health outcomes in endemic regions.

Keywords: Seasonal Malaria Chemoprevention (SMC), Severe malaria, Antimalarial drugs, Child health, Malaria control strategies.

INTRODUCTION

Malaria remains one of the leading causes of morbidity and mortality among children, particularly in sub-Saharan Africa, where it accounts for a significant proportion of childhood deaths [1–3]. Among the most vulnerable are children under the age of five, who are disproportionately affected by severe malaria and its complications. Efforts to control malaria have led to the development and implementation of various interventions, including vector control strategies and antimalarial treatments. One of the most promising approaches, particularly in areas with highly seasonal malaria transmission, is Seasonal Malaria Chemoprevention (SMC).

SMC is a preventive strategy designed to protect children during the peak transmission season by administering monthly doses of antimalarial drugs [4, 5]. The regimen, typically combining sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), has been endorsed by the World Health Organization (WHO) for use in regions where malaria transmission is seasonal and the burden of disease is high. This intervention targets a critical period when children are at the greatest risk, aiming to reduce the incidence of malaria infections and prevent progression to severe disease. Initial evidence has shown that SMC can significantly reduce the prevalence of malaria and its severe forms, lowering hospital admissions and mortality rates among children. Despite these promising outcomes, challenges such as drug resistance, logistical constraints, and adherence issues pose significant barriers to its broader implementation. Additionally, the seasonal focus of SMC limits its utility in regions with year-round malaria transmission.

This review seeks to critically assess the effectiveness of SMC in reducing severe malaria cases among children, examining its impact, operational challenges, and future prospects. By providing a comprehensive evaluation,

this review aims to inform strategies for optimizing SMC and integrating it into broader malaria control efforts to maximize its health benefits.

MECHANISMS AND IMPLEMENTATION OF SMC

Seasonal Malaria Chemoprevention (SMC) operates through the prophylactic administration of antimalarial drugs to prevent infection during periods of high malaria transmission [6]. The intervention primarily targets children under five, who are most vulnerable to severe malaria complications. The standard SMC regimen combines sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), drugs that work synergistically to clear existing parasitemia and provide sustained protection against reinfection [7]. Administered monthly over a three-to-four-month period, these drugs create a protective shield during the critical transmission season, significantly reducing the likelihood of infection and subsequent severe disease.

Implementation of SMC programs is designed to maximize accessibility and coverage. Community-based delivery models are commonly employed, wherein trained healthcare workers, often assisted by local volunteers, administer the medication directly to households. This approach minimizes barriers to access, ensuring that even children in remote areas can benefit from the intervention. High levels of community engagement and sensitization are critical to the program's success, as they foster trust and encourage adherence to the treatment schedule.

Achieving high coverage and adherence rates of SMC, typically exceeding 80%, is essential for the intervention's effectiveness [8, 9]. Robust supply chain management is also critical to ensure the timely delivery of drugs and prevent stockouts during the peak transmission period. Challenges such as logistical constraints, inadequate funding, and healthcare worker shortages can hinder program implementation, but innovative strategies, including digital tools for monitoring and coordination, are helping to address these issues. Overall, SMC's mechanisms and implementation are vital to its success in reducing malaria-related morbidity and mortality among children.

IMPACT OF SMC ON SEVERE MALARIA CASES

Seasonal Malaria Chemoprevention (SMC) has demonstrated a significant impact on reducing the incidence of severe malaria among children, particularly in regions with high seasonal transmission [10, 11]. By administering antimalarial drugs such as sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during peak transmission seasons, SMC provides effective protection against malaria infections that could progress to severe cases. The intervention specifically targets children under five, who are at the highest risk of developing severe complications such as cerebral malaria, severe anemia, and respiratory distress.

Evidence from numerous studies highlights the remarkable efficacy of SMC in reducing severe malaria cases. In areas where SMC is implemented with high coverage and adherence rates, malaria-related hospital admissions have declined by as much as 50% [12]. Mortality rates have also significantly decreased, underscoring the life-saving potential of the intervention. By preventing parasitemia during critical periods, SMC reduces the burden of severe disease, alleviating the associated strain on healthcare systems.

Beyond immediate health benefits, SMC has broader implications for child development. Repeated episodes of severe malaria can result in long-term cognitive impairments and stunted growth, both of which are mitigated by SMC. Moreover, by reducing the number of severe cases requiring hospitalization, SMC allows healthcare facilities to allocate resources to other pressing medical needs.

However, the effectiveness of SMC can vary based on factors such as baseline malaria prevalence, drug resistance, and community adherence. High adherence rates, exceeding 80%, are crucial for achieving optimal outcomes. Despite these challenges, SMC remains a vital tool in the fight against malaria. Its ability to significantly reduce severe cases among the most vulnerable populations demonstrates its indispensable role in malaria control programs, with the potential to contribute to broader efforts aimed at eliminating malaria as a public health threat.

CHALLENGES AND LIMITATIONS OF SMC

Despite its proven efficacy, the implementation of SMC faces several challenges. One of the primary concerns is the emergence of drug resistance. Resistance to SP and AQ has been reported in some areas, threatening the sustainability of SMC programs [13, 14]. Continuous monitoring of drug efficacy and the development of alternative regimens are crucial to address this issue.

Another significant limitation is the operational complexity of SMC delivery [15]. Ensuring high coverage requires meticulous planning and coordination, particularly in remote or conflict-affected regions. Supply chain disruptions, inadequate funding, and logistical constraints can hinder the timely delivery of medications, compromising the intervention's effectiveness.

Community acceptance and adherence also pose challenges. Although SMC programs are generally well-received, misconceptions about the drugs or the intervention's purpose can lead to hesitancy. Cultural barriers, language differences, and limited health literacy further complicate efforts to achieve high adherence rates. Addressing these challenges necessitates comprehensive community engagement and education initiatives.

Additionally, SMC is limited by its seasonal focus. While highly effective during peak transmission periods, the intervention does not address malaria transmission outside these seasons. This limitation underscores the need

for integrated approaches that combine SMC with other interventions, such as insecticide-treated nets (ITNs), indoor residual spraying (IRS), and improved access to prompt diagnosis and treatment.

FUTURE DIRECTIONS AND OPPORTUNITIES

To enhance the effectiveness of SMC, several strategies should be prioritized. First, the development and deployment of alternative drug regimens are essential to combat emerging resistance [16, 17]. Research into novel antimalarial compounds with extended prophylactic effects could provide new options for SMC programs. Additionally, integrating SMC with broader malaria control strategies can amplify its impact. For instance, combining SMC with mass drug administration (MDA) in high-transmission settings may further reduce malaria prevalence.

Digital technologies offer promising opportunities to optimize SMC delivery. Mobile health (mHealth) platforms can facilitate real-time monitoring, improve supply chain management, and support community sensitization efforts. These tools can also enhance data collection, enabling more precise tracking of coverage rates and health outcomes.

Furthermore, expanding the geographical scope of SMC could yield significant benefits. While currently concentrated in the Sahel region, extending SMC to other areas with seasonal malaria transmission patterns may protect additional vulnerable populations. However, such expansion requires careful consideration of regional epidemiological differences and the potential for resistance.

Finally, sustained investment in SMC programs is critical for their long-term success. Governments, international organizations, and donors must collaborate to secure adequate funding and resources. Strengthening health systems to support SMC implementation, including training healthcare workers and improving infrastructure, will further enhance the intervention's effectiveness.

CONCLUSION

Seasonal Malaria Chemoprevention has emerged as a highly effective intervention for reducing severe malaria cases among children in regions with seasonal transmission. By leveraging the prophylactic properties of antimalarial drugs, SMC has significantly reduced malaria-related morbidity and mortality, particularly in sub-Saharan Africa. However, challenges such as drug resistance, operational complexities, and seasonal limitations underscore the need for continuous innovation and integration with broader malaria control strategies.

Looking ahead, the future success of SMC depends on sustained investment, the development of alternative drug regimens, and the use of digital technologies to enhance delivery. By addressing these challenges and capitalizing on emerging opportunities, SMC can continue to play a pivotal role in the global fight against malaria, safeguarding the health and well-being of millions of children.

REFERENCES

1. Egwu, C.O., Aloke, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I., Aja, P.M., Offor, C.E., Obasi, N.A.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
2. Alum, E., Ugwu, P.-C., Simeon, E., Uti, D., Alum, B., Extension, K.P.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Egwu, C. O., Aloke, C., Chukwu, J., Nwankwo, J. C., Irem, C., Nwagu, K. E., ... & Obasi, N. A. (2023). Assessment of the antimalarial treatment failure in Ebonyi State, Southeast Nigeria. *Journal of Xenobiotics*, *13*(1), 16-26.
4. Afolabi, M.O., Sow, D., Ndiaye, J.L.A., Greenwood, B.: Safety and effectiveness of delivering mass drug administration for helminths through the seasonal malaria chemoprevention platform among Senegalese children: study protocol for a randomised controlled trial. Trials. 23, 627 (2022). https://doi.org/10.1186/s13063-022-06579-0
5. NDiaye, J.L., Cissé, B., Ba, E.H., Gomis, J.F., Ndour, C.T., Molez, J.F., Fall, F.B., Sokhna, C., Faye, B., Kouevijdin, E., Niane, F.K., Cairns, M., Trape, J.F., Rogier, C., Gaye, O., Greenwood, B.M., Milligan, P.J.M.: Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. PLOS ONE. 11, e0162563 (2016). https://doi.org/10.1371/journal.pone.0162563
6. Nikiema, S., Soulama, I., Sombié, S., Tchouatieu, A.-M., Sermé, S.S., Henry, N.B., Ouedraogo, N., Ouaré, N., Ily, R., Ouédraogo, O., Zongo, D., Djigma, F.W., Tiono, A.B., Sirima, S.B., Simporé, J.: Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa. Infection and Drug Resistance. 15, 4517–4527 (2022). https://doi.org/10.2147/IDR.S375197
7. Srinivasamurthy, S.K., Bairy, L.K.: Chemotherapy of Malaria and Other Protozoal Diseases. In: Paul, A., Anandabaskar, N., Mathaiyan, J., and Raj, G.M. (eds.) Introduction to Basics of Pharmacology and Toxicology: Volume 2 : Essentials of Systemic Pharmacology : From Principles to Practice. pp. 973–1026. Springer Nature, Singapore (2021)

8. Nuwa, A., Baker, K., Bonnington, C., Odongo, M., Kyagulanyi, T., Bwanika, J.B., Richardson, S., Nabakooza, J., Achan, J., Kajubi, R., Odong, D.S., Nakirunda, M., Magumba, G., Beinomugisha, G., Marasciulo-Rice, M., Abio, H., Rassi, C., Rutazaana, D., Rubahika, D., Tibenderana, J., Opigo, J.: A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda. Malar J. 22, 63 (2023). https://doi.org/10.1186/s12936-023-04488-4
9. Salangwa, C., Lusale, D.: Assessment of attitudes and practices influencing adherence to seasonal malaria chemoprevention (SMC) in children >5 years of age: The case of Rural Embangweni Mzimba district, Malawi., https://www.researchsquare.com/article/rs-2863116/v1, (2023)
10. Nikiema, S., Soulama, I., Sombié, S., Tchouatieu, A.-M., Sermé, S.S., Henry, N.B., Ouedraogo, N., Ouaré, N., Ily, R., Ouédraogo, O., Zongo, D., Djigma, F.W., Tiono, A.B., Sirima, S.B., Simporé, J.: Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa. Infection and Drug Resistance. 15, 4517–4527 (2022). https://doi.org/10.2147/IDR.S375197
11. Kirakoya-Samadoulougou, F., De Brouwere, V., Fokam, A.F., Ouédraogo, M., Yé, Y.: Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. Malar J. 21, 143 (2022). https://doi.org/10.1186/s12936-022-04172-z
12. Nikiema, S., Soulama, I., Sombié, S., Tchouatieu, A.-M., Sermé, S.S., Henry, N.B., Ouedraogo, N., Ouaré, N., Ily, R., Ouédraogo, O., Zongo, D., Djigma, F.W., Tiono, A.B., Sirima, S.B., Simporé, J.: Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa. Infection and Drug Resistance. 15, 4517–4527 (2022). https://doi.org/10.2147/IDR.S375197
13. Traore, A., Donovan, L., Sawadogo, B., Ward, C., Smith, H., Rassi, C., Counihan, H., Johansson, J., Richardson, S., Savadogo, J.R., Baker, K.: Extending seasonal malaria chemoprevention to five cycles: a pilot study of feasibility and acceptability in Mangodara district, Burkina Faso. BMC Public Health. 22, 442 (2022). https://doi.org/10.1186/s12889-022-12741-9
14. Flegg, J.A., Humphreys, G.S., Montanez, B., Strickland, T., Jacome-Meza, Z.J., Barnes, K.I., Raman, J., Guerin, P.J., Sibley, C.H., Otienoburu, S.D.: Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990–2020. PLOS Computational Biology. 18, e1010317 (2022). https://doi.org/10.1371/journal.pcbi.1010317
15. Bekele, A.A., Mahesh, G., Ingle, P.V.: Enhancing SMCs' competitiveness through improving material supply chain management practice. International Journal of Construction Management. 25, 77–88 (2025). https://doi.org/10.1080/15623599.2024.2304471
16. Rasmussen, C., Alonso, P., Ringwald, P.: Current and emerging strategies to combat antimalarial resistance. Expert Review of Anti-infective Therapy. 20, 353–372 (2022). https://doi.org/10.1080/14787210.2021.1962291
17. Ippolito, M.M., Moser, K.A., Kabuya, J.-B.B., Cunningham, C., Juliano, J.J.: Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy. Curr Epidemiol Rep. 8, 46–62 (2021). https://doi.org/10.1007/s40471-021-00266-5

CITE AS: Kirenyo Nalubega F. (2024). Assessing the Effectiveness of Seasonal Malaria Chemoprevention (SMC) in Reducing Severe Malaria Cases among Children. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(2):106-109.